As shown in Table 1, the median follow‐up was 66.1 months in cluster A and 43.8 months in cluster B. In cluster A, patients are more likely to possess lower tumor grade, positive ER status, positive PR status, low frequency of p53 mutation, and negative Ki-67 status than those in cluster B. When we stratified the patients by clinicopathologic factors, this senescence-related subtype could not independently predict the prognosis. The gene discussed is ESR1; the disease is neoplasm.